Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide

Diabetes. 1989 Jul;38(7):902-5. doi: 10.2337/diab.38.7.902.

Abstract

We examined the effect of glucagonlike peptides (GLPs), which are cleaved from preproglucagon in the enteroglucagon cells, on rat endocrine pancreas with the isolated perfused system. GLP-I-(7-36)-amide, a truncated form of full-sequence GLP-I-(1-37), showed a potent inhibitory effect on glucagon secretion. This inhibitory effect of GLP-I-(7-36)-amide was demonstrated at concentrations of 0.25, 2.5, and 25 nM in 11.2 and 2.8 mM glucose. In contrast, insulin release was significantly stimulated by GLP-I-(7-36)-amide at its concentration from 0.025 to 25 nM in a high glucose concentration, whereas in a low glucose concentration, the stimulation was seen only at the highest concentration (25 nM). Neither GLP-I-(1-37) nor GLP-II showed any effect on glucagon and insulin release. Although several gastrointestinal hormones have been nominated as incretins, none of them may suppress the glucagon secretion. A truncated form of GLP-I, GLP-I-(7-36)-amide thus seems to be a unique incretin that exerts glucagonostatic action.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Glucagon / metabolism*
  • Glucagon-Like Peptide 1
  • Glucagon-Like Peptides
  • Glucose / pharmacology
  • Insulin / metabolism*
  • Male
  • Pancreas / drug effects
  • Pancreas / metabolism*
  • Peptide Fragments*
  • Peptides / pharmacology*
  • Rats
  • Rats, Inbred Strains

Substances

  • Insulin
  • Peptide Fragments
  • Peptides
  • glucagon-like peptide 1 (7-36)amide
  • Glucagon-Like Peptides
  • glucagon-like-immunoreactivity
  • glucagon-like peptide 1 (1-37)
  • Glucagon-Like Peptide 1
  • Glucagon
  • Glucose